Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. - Hayashi H; Cho BC; Kim YJ; Lee SH; Danchaivijitr P; Alip A; Xiong H; How SH; Chang GC; Yang JC; Yamanaka Y; Nahit Şendur MA; et al. (Lung cancer (Amsterdam, Netherlands), 2026)